Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma
CTR20240078Phase 2Active
- Sponsor
- Hengrui Yuanzheng
- Start
- Aug 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of MASCT-1 in soft tissue sarcoma (STS), sponsored by Hengrui Yuanzheng. Started Aug 2024; status: active.
02
Drugs
MASCT-1
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20240078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240078.